The availability of commercial antibodies for a myriad of scientific applications has had a profound positive impact on life science research. It's not surprising that the global antibody market, including therapeutics, diagnostics, and research, is now estimated at $70-75 billion.
And yet, almost half of 400 antibody users surveyed by 1DegreeBio in 2012 reported that that in 50% of cases, their antibodies did not work as expected. That’s a lot of failed experiments—and a lot of money wasted.
